These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 25695403)

  • 21. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.
    Decramer M; Celli B; Kesten S; Lystig T; Mehra S; Tashkin DP;
    Lancet; 2009 Oct; 374(9696):1171-8. PubMed ID: 19716598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
    Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
    Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial.
    Lazaar AL; Miller BE; Donald AC; Keeley T; Ambery C; Russell J; Watz H; Tal-Singer R;
    Respir Res; 2020 Jun; 21(1):149. PubMed ID: 32532258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial.
    Nair P; Gaga M; Zervas E; Alagha K; Hargreave FE; O'Byrne PM; Stryszak P; Gann L; Sadeh J; Chanez P;
    Clin Exp Allergy; 2012 Jul; 42(7):1097-103. PubMed ID: 22702508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.
    Kinoshita M; Lee SH; Hang LW; Ichinose M; Hosoe M; Okino N; Prasad N; Kramer B; Fukuchi Y;
    Respirology; 2012 Feb; 17(2):379-89. PubMed ID: 22122202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
    Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
    Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium.
    Vogelmeier C; Aquino TO; O'Brien CD; Perrett J; Gunawardena KA
    COPD; 2012 Apr; 9(2):111-20. PubMed ID: 22458939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
    Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group.
    Maesen FP; Smeets JJ; Sledsens TJ; Wald FD; Cornelissen PJ
    Eur Respir J; 1995 Sep; 8(9):1506-13. PubMed ID: 8575576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease.
    Brightling CE; McKenna S; Hargadon B; Birring S; Green R; Siva R; Berry M; Parker D; Monteiro W; Pavord ID; Bradding P
    Thorax; 2005 Mar; 60(3):193-8. PubMed ID: 15741434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
    Rabe KF; Watz H; Baraldo S; Pedersen F; Biondini D; Bagul N; Hanauer G; Göhring UM; Purkayastha D; Román J; Alagappan VKT; Saetta M
    Lancet Respir Med; 2018 Nov; 6(11):827-836. PubMed ID: 30224319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients.
    Kerstjens HA; Bjermer L; Eriksson L; Dahlström K; Vestbo J
    Respir Med; 2010 Sep; 104(9):1297-303. PubMed ID: 20466530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.
    Rabe KF; Bateman ED; O'Donnell D; Witte S; Bredenbröker D; Bethke TD
    Lancet; 2005 Aug 13-19; 366(9485):563-71. PubMed ID: 16099292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-inflammatory effects of salmeterol/fluticasone propionate 50/250 mcg combination therapy in Japanese patients with chronic obstructive pulmonary disease.
    Asai K; Kobayashi A; Makihara Y; Johnson M
    Int J Chron Obstruct Pulmon Dis; 2015; 10():803-11. PubMed ID: 25945045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
    Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II Study of Single/Repeated Doses of Acumapimod (BCT197) to Treat Acute Exacerbations of COPD.
    Strâmbu IR; Kobalava ZD; Magnusson BP; MacKinnon A; Parkin JM
    COPD; 2019 Dec; 16(5-6):344-353. PubMed ID: 31682162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Walking a tightrope: targeting neutrophils to treat chronic obstructive pulmonary disease.
    Aaron SD
    Am J Respir Crit Care Med; 2015 May; 191(9):971-2. PubMed ID: 25932758
    [No Abstract]   [Full Text] [Related]  

  • 39. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects.
    Holz O; Khalilieh S; Ludwig-Sengpiel A; Watz H; Stryszak P; Soni P; Tsai M; Sadeh J; Magnussen H
    Eur Respir J; 2010 Mar; 35(3):564-70. PubMed ID: 19643947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
    Dal Negro RW; Visconti M; Turco P
    Pulm Pharmacol Ther; 2015 Aug; 33():47-51. PubMed ID: 26116425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.